At Cigna, we aim to protect our clients and customers from unnecessary costs when clinically appropriate lower cost alternatives are available. Even more important than controlling cost, is managing drug safety. Which is why we have an ongoing review to manage the use of dangerous narcotic medications (also called opioids).
Beginning July 1, 2017, we will use tighter drug management practices to promote safer use of opioids
Drug overdose is the leading cause of accidental death in the U.S., with opioid addiction driving this epidemic.1 It’s for this reason that on July 1, 2017, we are putting prior authorizations and quantity limits in place for first time opioid users based on Centers for Disease Control and Prevention (CDC) guidelines. Implementing these changes to our drug management (also called utilization management) programs will make the use of opioids safer for our customers. Below are details to the drug management practices that may apply to your formulary.
Customer’s newly prescribed long-acting opioid may be subject to a prior authorization
Customer’s newly prescribed short-acting opioid may be subject to quantity limits
What you should know about those receiving a first time opioid prescription:
Our priority is to maintain affordability and drug safety for our clients and customers.